UiPath (NYSE:PATH) Trading Down 0.4%

UiPath Inc. (NYSE:PATH - Get Free Report) shares fell 0.4% during trading on Friday . The company traded as low as $18.79 and last traded at $18.97. 1,170,693 shares changed hands during mid-day trading, a decline of 87% from the average session volume of 8,853,152 shares. The stock had previously closed at $19.04.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on PATH. Canaccord Genuity Group raised their target price on UiPath from $27.00 to $30.00 and gave the stock a "buy" rating in a research report on Friday, March 15th. DA Davidson raised their target price on UiPath from $20.00 to $24.00 and gave the stock a "neutral" rating in a research report on Thursday, March 14th. TD Cowen raised their target price on UiPath from $25.00 to $28.00 and gave the stock an "outperform" rating in a research report on Thursday, March 14th. Needham & Company LLC reaffirmed a "buy" rating and set a $30.00 target price on shares of UiPath in a research report on Wednesday, March 20th. Finally, Royal Bank of Canada reaffirmed a "sector perform" rating and set a $29.00 target price on shares of UiPath in a research report on Monday, April 1st. Nine investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. According to data from MarketBeat.com, UiPath has a consensus rating of "Moderate Buy" and a consensus price target of $27.41.

UiPath Trading Down 1.6 %

The company has a market cap of $10.66 billion, a P/E ratio of -110.23 and a beta of 0.96. The business's fifty day moving average is $22.82 and its 200 day moving average is $21.45.

UiPath (NYSE:PATH - Get Free Report) last posted its quarterly earnings results on Wednesday, March 13th. The healthcare company reported $0.06 EPS for the quarter, topping analysts' consensus estimates of ($0.04) by $0.10. The company had revenue of $405.25 million for the quarter, compared to analysts' expectations of $383.32 million. UiPath had a negative net margin of 6.87% and a negative return on equity of 3.29%. As a group, research analysts expect that UiPath Inc. will post -0.04 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Ashim Gupta sold 40,000 shares of the stock in a transaction dated Thursday, April 4th. The stock was sold at an average price of $21.66, for a total transaction of $866,400.00. Following the sale, the chief financial officer now owns 660,762 shares of the company's stock, valued at approximately $14,312,104.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold a total of 72,000 shares of company stock worth $1,591,360 over the last 90 days. Corporate insiders own 31.03% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Intech Investment Management LLC boosted its stake in UiPath by 3.1% in the 4th quarter. Intech Investment Management LLC now owns 14,324 shares of the healthcare company's stock worth $356,000 after purchasing an additional 426 shares during the period. 180 Wealth Advisors LLC boosted its stake in UiPath by 0.3% in the 4th quarter. 180 Wealth Advisors LLC now owns 188,950 shares of the healthcare company's stock worth $4,497,000 after purchasing an additional 492 shares during the period. Bleakley Financial Group LLC boosted its stake in UiPath by 4.9% in the 4th quarter. Bleakley Financial Group LLC now owns 12,691 shares of the healthcare company's stock worth $315,000 after purchasing an additional 598 shares during the period. Simplicity Solutions LLC boosted its stake in UiPath by 4.9% in the 4th quarter. Simplicity Solutions LLC now owns 12,691 shares of the healthcare company's stock worth $315,000 after purchasing an additional 598 shares during the period. Finally, GAMMA Investing LLC raised its holdings in shares of UiPath by 40.2% in the 1st quarter. GAMMA Investing LLC now owns 2,204 shares of the healthcare company's stock valued at $50,000 after acquiring an additional 632 shares in the last quarter. Institutional investors own 62.50% of the company's stock.

UiPath Company Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, and Japan. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.